Publication:
Usefulness of serum M30 and M65 levels to predict response to neoadjuvant chemotherapy in patients with breast cancer.

Placeholder

Organizational Units

Program

Authors

Turk, HM
Kocyigit, A
Aliyev, A
Celik, RS
Seker, MESUT
Coban, E
Demir, T
Baydas, T

Advisor

Language

Publisher

Journal Title

Journal ISSN

Volume Title

Abstract

Objective: M30 and M65 levels reflect tumor cell activity in patients with epithelial cancer. Cytokeratin 18 is one of the cell skeletal elements. M30 is a apoptotic marker of cytokeratin 18. M65 levels are both an apoptosis and a necrosis marker. The aim of our study was to determine the predictive value of M30 and M65 levels in neoadjuvant treatment of breast cancer.

Description

Source:

Keywords:

Keywords

Citation

Turk H., Aliyev A., Celik R., Seker M., Coban E., Demir T., Baydas T., Kocyigit A., -Usefulness of serum M30 and M65 levels to predict response to neoadjuvant chemotherapy in patients with breast cancer.-, Current problems in cancer, ss.100497, 2019

Endorsement

Review

Supplemented By

Referenced By

0

Views

0

Downloads

View PlumX Details


Sustainable Development Goals

Thumbnail Image
Goal